Beigene

This study tested a drug called zanubrutinib in 55 Japanese patients with certain types of blood cancers (B-cell malignancies) that had come back or stopped responding to previous treatments. The goal was to check the drug's safety and how well it works. Patients took the drug by…

This study tested a new drug (ociperlimab) combined with either tislelizumab or rituximab in 53 people whose diffuse large B-cell lymphoma had come back or stopped responding to treatment. The main goals were to check safety and find the best dose. Researchers also looked at whet…

This study tested a new drug called BGB-10188, alone or combined with other cancer drugs, in 97 people with certain blood cancers (like lymphoma and leukemia) or advanced solid tumors. The main goals were to find safe doses and check for side effects. The trial was completed, but…

This study tested three different immunotherapy drugs (surzebiclimab, alcestobart, and tislelizumab) given together to people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to find safe doses and see if the combinations could sh…

This study tested a drug called zanubrutinib in 96 people with certain types of B-cell lymphoma who had severe side effects from similar drugs (ibrutinib or acalabrutinib). The goal was to see if zanubrutinib caused fewer or milder side effects while still controlling the cancer.…

This study tested whether giving the drug tislelizumab along with chemotherapy or chemoradiation before surgery could completely eliminate esophageal cancer in 70 patients. The goal was to see if no cancer remained in the removed tissue. The approach uses PET scans to guide treat…

This study tested giving the immunotherapy drug tislelizumab, alone or with other treatments, before surgery for stage II to IIIA non-small cell lung cancer. The goal was to see if these treatments could shrink tumors and improve outcomes. 121 adults with operable lung cancer too…

This study tested a new drug called gimistotug (BGB-A445) combined with other investigational drugs in 35 people with advanced non-small cell lung cancer who had already received standard treatments. The main goal was to see if the combination could shrink tumors. The trial is no…

This early-phase study tested a combination of two experimental drugs (BGB-283 and PD-0325901) in 91 adults with advanced or metastatic solid tumors that had stopped responding to standard treatments. The main goals were to check safety and see if the drugs could shrink tumors. T…

This study tested a new drug, tislelizumab, against the standard treatment sorafenib for adults with advanced liver cancer that cannot be removed by surgery. Over 680 participants were randomly assigned to receive one of the two treatments. The goal was to see which drug worked b…

This early-phase study tested a new drug (BGB-A445) alone and with another drug (tislelizumab) in 204 people with advanced solid tumors like lung, head and neck, and nasopharyngeal cancers. The main goals were to check safety and find the best dose. This is not a cure, but aims t…

This study tested whether adding a new drug, ociperlimab, to a standard immunotherapy (tislelizumab) and chemotherapy could help people with advanced non-small cell lung cancer that cannot be removed by surgery or has spread. The trial involved 272 adults who had not received pri…

This study tested the drug tislelizumab given before surgery in 33 people with early-stage (stage II-III) colorectal cancer that has specific genetic changes (MSI-H or dMMR). The goal was to see if the drug could shrink or eliminate the tumor before surgical removal. The main mea…

This study tested a drug called zanubrutinib in 65 adults with a hard-to-treat type of lymphoma (DLBCL) that has a specific gene change (CD79B mutation) and has come back or not responded to prior treatment. Participants took the drug as a pill and were monitored for tumor shrink…

This study tested a drug called tislelizumab in 46 people whose Hodgkin lymphoma had come back or didn't respond to prior treatments. The goal was to see if the drug could shrink or eliminate tumors. Participants received the drug until their disease worsened or side effects beca…

This study tested whether adding zanubrutinib to obinutuzumab works better than obinutuzumab alone for adults with follicular lymphoma that came back or didn't respond to prior treatments. About 217 participants were randomly assigned to one of the two groups. The main goal was t…

This study tested whether adding the drug tislelizumab to standard chemoradiotherapy helps people with localized esophageal squamous cell carcinoma. 370 participants received either tislelizumab or a placebo alongside their cancer treatment. The main goal was to see if the drug c…

This early-stage study tested a new drug, BGB-23339, in 92 healthy adults to see if it is safe and how the body handles it. Participants took single or multiple doses, and the effect of food was also checked. The goal was to gather safety information, not to treat any disease.

This study looked at how two different tablet forms of BGB-43395 are absorbed by the body and whether food changes that. 51 healthy adults took a single dose of the drug. The goal was to gather information, not to treat any disease.

This study looked at how two common drugs—phenytoin and itraconazole—change the way the body processes BGB-16673. It involved 37 healthy adults aged 18 to 65. The goal was to measure drug levels in the blood, not to treat any disease.